Abstracts

Plasma Proteomics Signature of People Living With HIV, With NAFLD, With and Without Obesity

Background: Non-alcoholic fatty liver disease (NAFLD) is a leading cause of liver-related morbidity in people living with HIV (PLHIV). Obesity is an important risk factor but NAFLD also occurs in lean PLHIV, with possible different underlying pathophysiology. Proteomics facilitate biomarker discovery and may help identify biological mechanisms. Methods: We analyzed data from 1050 PLHIV with…

Liver Steatosis Is Not Associated With Endothelial Function or Hormone Use in Transgender Women

Background: Transgender women (TGW) present disproportionate chronic diseases burden. Nevertheless, very little is known about inflammation-related chronic diseases among TGW in low and middle-income countries (LMIC), especially in the context of HIV infection and gender-affirming hormone therapy (GAHT). We aimed to assess the association of liver steatosis with subclinical atherosclerosis measured by brachial artery flow-mediated…

Predictors of Liver-Related Events Following DAA HCV Cure in PWH With Advanced Fibrosis/Cirrhosis

Background: We assessed prognostic factors of liver-related events (LRE) among HCV-coinfected PWH with advanced fibrosis (AF) or compensated cirrhosis (CC) with SVR following all-oral direct antiviral therapy (DAA-Rx). Methods: We leveraged 3 prospective observational studies in Spain to select coinfected PWH with AF (biopsy confirmed F3 or liver stiffness [LS] value > 9.9 and ≤…

Nationwide HCV Elimination Program and the Status of Microelimination in People With HIV in Taiwan

Background: Evidence from Western countries suggests that nationwide hepatitis C virus (HCV) elimination programs, typically coupled with the expansion of HCV testing and direct-acting antiviral (DAA) treatments, could mitigate new HCV infections among people with HIV (PWH). However, real-world data from Asia-Pacific region remained scarce, and the impact of HCV testing and DAA treatment program…

Teropavimab and Zinlirvimab Sensitivity in People Living With MDR HIV-1: PRESTIGIO Registry Data

Background: Broadly neutralizing antibodies (bNAbs) are being investigated as long-acting antiviral therapies, but sensitivity to bNAbs in persons with multidrug-resistant HIV is unknown. Here, we characterized sensitivity to teropavimab (GS-5423; 3BNC117-LS; TAB) and zinlirvimab (GS-2872; 10-1074-LS; ZAB) in people living with 4-class drug-resistant HIV (4DR-PWH). Methods: Multicenter, observational study using plasma or peripheral blood mononuclear…

Predictors of Failure to COVID-19 Early Therapies and Drugs Efficacy Comparison by Emulation Trial

Background: Although widespread vaccination and lower pathogenicity of the omicron variant had drastically reduced the rate of COVID-19-related hospitalization/death (CovH/D), real-world evidence can help to identify categories still at risk of severe outcomes and inform on the efficacy of different treatments used. Methods: Multicenter cohort of high-risk outpatients (pts) treated with monoclonal antibodies (mAbs) or…

AGILE CST-8 Phase I Trial of Combined Nirmatrelvir/r and Molnupiravir for Mild-Moderate COVID-19

Background: AGILE (NCT04746183) is the UK platform for early-phase evaluation of COVID-19 antivirals. AGILE-CST-8 is a phase I, adaptive, dose de-escalation study of combination nirmatrelvir/ritonavir plus molnupiravir Methods: Adults with a positive lateral flow test, within 5 days of mild-moderate symptoms were randomised (2:1, open-label) to nirmatrelvir/ritonavir plus molnupiravir versus Standard of Care (SoC). Exclusions…